Crispr Gene Editing Is Coming for the Womb | WIRED
Posted: April 18, 2019 at 3:49 am
William Peranteau is the guy parents call when theyve received the kind of bad news that sinks stomachs and wrenches hearts. Sometimes its a shadow on an ultrasound or a few base pairs out of place on a prenatal genetic test, revealing that an unborn child has a life-threatening developmental defect. Pediatric surgeons like Peranteau, who works at Childrens Hospital of Philadelphia, usually cant try to fix these abnormalities until their patients leave their mothers bodies behind. And by then it might be too late.
Its with the memory of the families he couldnt help in the back of his mind that Peranteau has joined a small group of scientists trying to bring the fast-moving field of gene editing to the womb. Such editing in humans is a long way off, but a spate of recent advances in mouse studies highlight its potential advantages over other methods of using Crispr to snip away diseases. Parents confronted with an in utero diagnosis are often faced with only two options: terminate the pregnancy or prepare to care for a child who may require multiple invasive surgeries over the course of their lifetime just to survive. Prenatal gene editing may offer a third potential path. What we see as the future is a minimally invasive way of treating these abnormalities at their genetic origin instead, says Peranteau.
To prove out this vision, Peranteau and colleagues at the University of Pennsylvania injected Crispr editing components, encoded in a virus, into the placentas of pregnant mice whose unborn pups were afflicted with a lethal lung-disease-causing mutation. When the fetuses breathed in the amniotic fluid they also inhaled the Crispr bits, which went to work editing the DNA inside their rapidly dividing alveolar progenitor cells. These cells give rise to many types of cells that line the lungsincluding ones that secrete a sticky substance that keeps the lungs from collapsing every time you breathe. Mutations to proteins that make up this secretion are a major source of congenital respiratory conditions. All of the mice with the mutation died within a few hours of birth. Of those edited with Crispr, about a quarter survived. The results were published in todays issue of Science Translational Medicine.
Its the second proof of concept from the group of scientists in the past year. In October, they published a paper describing a slightly different procedure to edit mutations that lead to a lethal metabolic disorder. By changing a single base pair in the liver cells of prenatal mice, Peranteaus team was able to rescue nearly all of the mouse pups. Other recent successes include unborn mice cured of a blood disorder called beta-thalassemia following a prenatal injection of Crispr, carried out last year by a team at Yale and Carnegie Mellon.
Though the field is still in its infancy, its pioneers believe that many of the problems Crispr-based therapies have to contend withlike reaching enough of the right cells and evading the human immune systemcan be solved by treating patients while they are still in the womb.
If youre trying to edit cells in an adult organ, theyre not proliferating, so you have to reach a lot of them to have any impact, says Edward Morrisey, a cardiologist at the University of Pennsylvania, who coauthored the latest study. Fetuses, on the other hand, are still developing, which means their cells are in a state of rapid division as they grow into new tissues. The earlier in life you can edit, the more those genetic changes will multiply and propagate through developing organs. Morriseys mice might have only been born with the genetic edit in about 20 percent of their lung cells, but 13 weeks later, the correction had spread to the entire surface of the lung. Theyve actually outcompeted the nonedited cells, because those cells are very sick, says Morissey.
For lung diseases in particular, this represents a huge advantage. As soon as a baby leaves the watery world of the womb, its lung cells start secreting a barrier of mucus mixed with surfactant, to keep any dust or viruses or other foreign objects, including Crispr components, from reaching those tissues. A developing fetus also has a less aggressive immune system than a human whos been exposed to the outside world. So its less likely to mount an attack on Crispr components, which do, after all, originate in the bacterial kingdom.
Now, you might be thinking, if editing earlier is better, why not edit an embryo right after its been fertilized, when its only a cell or two old? But this technique, known as germline editing (you might remember it from last years Chinese Crispr baby scandal), is a much more complicated ethical endeavor. Editing at that stage would pass on any changes to every cell, including the ones that would go on to make sperm or eggs. This kind of editing is effectively banned in the United States, following a directive from Congress to the US Food and Drug Administration to not allow any clinical trials involving genetically modified human embryos. (The ban, which has to be renewed annually, was most recently reaffirmed in February of 2019). The other thing though, is that getting an accurate diagnosis when an embryo is only a few cells old can be tricky. Waiting long enough to get a visual on a fetus along with other vital signs can provide important clues as to the severity of the condition. It gets us right in that sweet spot to treat a disease at the very beginning, basically as soon as its diagnosed, says Peranteau.
But there are still safety issues to resolve. For one thing, in utero editing involves two patients, not just one. In the process of curing a child, this technique would potentially expose a healthy bystanderthe motherto a treatment that provides no potential benefit and only potential risks, including dangerous immune reactions. And because the editing is taking place inside her reproductive tract, some wayward Crispr components might wend their way up her fallopian tubes and into her ovaries, potentially making changes to other, unfertilized eggs. A lot more science will need to be done to better assess these risks. To give you an idea of how long these things can take, consider that in utero gene therapyan older approach that entails replacing a defective gene with a functioning one using a viruswas first proposed back in the mid-1990s following a series of positive proof of concept studies in mice. Today, only a single clinical trial is in progress.
This is not a panacea for curing every genetic disease thats out there, says Peranteau. But he believes that a Crispr approach will be able to piggyback on the work of the gene therapy field, and may offer a new way forward for at least some of his patients. At some point in the futurenot tomorrow or the next day, years from nowI think in utero editing would provide hope for families that today have none.
Read more from the original source:
Crispr Gene Editing Is Coming for the Womb | WIRED
- What's the Latest in CRISPR Gene-Editing Technology? - Technology Networks - March 12th, 2024
- In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasis | Oncogene - Nature.com - March 12th, 2024
- Investigating the mechanisms underlying resistance to chemoterapy and to CRISPR-Cas9 in cancer cell lines ... - Nature.com - March 12th, 2024
- Here's Why CRISPR Therapeutics Stock Climbed 34% in February - The Motley Fool - March 12th, 2024
- SXSW Panel Recap: The First CRISPR Foods Have Arrived - Austin Chronicle - March 12th, 2024
- CRISPR-Cas systems: Overview, innovations and applications in human ... - March 4th, 2024
- CRISPR Therapeutics Stock Has 32% Upside, According to 1 Wall Street Analyst - The Motley Fool - March 4th, 2024
- Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and Hold - The Motley Fool - March 4th, 2024
- MEGA-CRISPR tool gives a power boost to cancer-fighting cells - Nature.com - February 23rd, 2024
- 3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential - InvestorPlace - February 23rd, 2024
- CRISPR 'will provide cures for genetic diseases that were incurable before,' says renowned biochemist Virginijus iknys - Livescience.com - February 23rd, 2024
- Opinion: The Promise and Challenges of CRISPR-Based Treatments - BioSpace - February 23rd, 2024
- There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump - Simply Wall St - February 23rd, 2024
- Move over, CRISPR: RNA-editing therapies pick up steam - Nature.com - February 23rd, 2024
- If You Invested $10000 in CRISPR Therapeutics in 2019, This Is How Much You Would Have Today - The Motley Fool - February 23rd, 2024
- CRISPR Therapeutics Joins Rank Of Stocks With 95-Plus Composite Rating - Investor's Business Daily - February 23rd, 2024
- CRISPR Therapeutics (NASDAQ:CRSP) Hits New 12-Month High on Better-Than-Expected Earnings - AmericanBankingNEWS - February 23rd, 2024
- CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewswire - February 23rd, 2024
- CRISPR Therapeutics AG (CRSP) Moves 6.9% Higher: Will This Strength Last? - Yahoo Finance - February 23rd, 2024
- Advancements in RNA for HIV Treatment: CRISPR Cas9, mRNA Therapeutics, and Next-Generation Sequencing ... - Medriva - February 23rd, 2024
- Intellia Therapeutics Charges Ahead: A Glimpse into the Future of CRISPR-Based Therapies - BNN Breaking - February 23rd, 2024
- The FDA Approved The First CRISPR-Based Therapy. What's Next? - Science Friday - February 5th, 2024
- Using CRISPR technology, researchers succeed in growing tomatoes that consume less water without compromising yield - Phys.org - February 5th, 2024
- CRISPR-Cas9 gene-editing tool repairs defective T cells to treat rare hereditary disease - News-Medical.Net - February 5th, 2024
- New CRISPR Technology Increases Recognition of Cancer Cells by the Immune System - Inside Precision Medicine - February 5th, 2024
- Is CRISPR Therapeutics a Buy in the New Bull Market? - The Motley Fool - February 5th, 2024
- Stocks Flashing Renewed Technical Strength: CRISPR Therapeutics - Investor's Business Daily - February 5th, 2024
- AI at Davos, new CRISPR therapies and health tech's bad marketing - Marketplace - January 20th, 2024
- FDA expands use of newly approved CRISPR therapy - Axios - January 20th, 2024
- CRISPR-based therapy receives expanded approval for beta thalassemia - STAT - January 20th, 2024
- CRISPR Therapeutics And Vertex's CRISPR Breakthrough: How And Why They Got There First - Scrip - January 20th, 2024
- Pharmalittle: We're reading about a CRISPR approval, selling meds directly to patients, and more - STAT - January 20th, 2024
- Here's Why CRISPR Therapeutics Stock Rose 54% Last Year - The Motley Fool - January 20th, 2024
- Vertex's CRISPR Gene Therapy Lands Another FDA Nod in a Rare Blood Disease - MedCity News - January 20th, 2024
- Groundbreaking CRISPR/Cas9-based Genome Editing Therapy Secured the Second FDA Approval - geneonline - January 20th, 2024
- What Does It Mean for Investors if CRISPR Therapeutics Gets Bought Out in 2024? - The Motley Fool - January 20th, 2024
- First FDA-approved CRISPR-based gene therapy cleared for 2nd indication - LabPulse - January 20th, 2024
- CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY ... - GlobeNewswire - January 20th, 2024
- CRISPR Gene Editing And Its Role In Hematology | TheHealthSite.com - TheHealthSite - January 20th, 2024
- Doudna institute hatches plan to 'cure hundreds of diseases' left behind by CRISPR revolution - STAT - January 11th, 2024
- Discover the recent progress of nonviral delivery carriers for CRISPR/Cas9 systems - News-Medical.Net - January 11th, 2024
- How CRISPR could yield the next blockbuster crop - Nature.com - January 11th, 2024
- Weight-loss drugs, malaria vaccines and more: CRISPR innovations headline the science breakthroughs of 2023 - Genetic Literacy Project - January 11th, 2024
- CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook - GlobeNewswire - January 11th, 2024
- CRISPR Therapeutics AG (CRSP) 42nd Annual J.P. Morgan Healthcare Conference (Transcript) - Seeking Alpha - January 11th, 2024
- CRISPR to be used to genetically modify crops - FoodNavigator.com - January 11th, 2024
- Casgevy approval unlikely to be followed up by another CRISPR drug in near future - BioPharma-Reporter.com - January 11th, 2024
- Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY, for the Treatment of Sickle Cell ... - Business Wire - January 11th, 2024
- The Science Behind CRISPR: Germline Genome Editing and Its Applications - Medriva - January 11th, 2024
- Here's Why 2024 Could Be a Big Year for CRISPR Therapeutics - The Motley Fool - January 11th, 2024
- Revolutionizing acne treatment with CRISPR technology - Labiotech.eu - January 11th, 2024
- What Is CRISPR Gene Editing and How Does It Work? - December 25th, 2023
- This first CRISPR treatment is just the beginning. Heres what's next - Fast Company - December 25th, 2023
- The Age of Crispr Medicine Is Here - WIRED - December 25th, 2023
- 6 Words That Explain Why CRISPR Stock Isn't Soaring Despite the Recent FDA Approval for Its Gene-Editing Therapy - Yahoo Finance - December 25th, 2023
- Crispr Therapeutics Medical Chief Morrow to Resign - The Wall Street Journal - December 25th, 2023
- Crispr Therapeutics chief medical officer is resigning - MarketWatch - December 25th, 2023
- 3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow - Yahoo Finance - December 25th, 2023
- CAR T Therapy May Cause Rare Cancer & How CRISPR Could Be The Solution - Forbes - December 25th, 2023
- CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical Chief - InvestorPlace - December 25th, 2023
- With the promise of saving millions of lives, CRISPR medicine is born - EL PAS USA - December 25th, 2023
- Casgevy: the world's first CRISPR therapy - Epigram - December 25th, 2023
- The Basics of CRISPR Gene Editing - Cleveland Clinic Health Essentials - November 27th, 2023
- Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing - November 27th, 2023
- What is CRISPR gene editing, and how does it work? - The Conversation - October 16th, 2023
- What is CRISPR/Cas9? - PMC - National Center for Biotechnology Information - October 16th, 2023
- CRISPR, 10 Years On: Learning to Rewrite the Code of Life - April 26th, 2023
- What Is CRISPR, and Why Is It So Important? - Scientific American - March 23rd, 2023
- Global CRISPR Technology Market Is Projected To Grow At A 22% Rate Through The Forecast Period - EIN News - March 14th, 2023
- What is CRISPR and why is it controversial? | CNN - February 2nd, 2023
- CRISPR | Description, Technology, Uses, & Ethical Concerns - February 2nd, 2023
- In vivo CRISPR screening reveals nutrient signaling processes ... - PubMed - December 12th, 2022
- What is CRISPR? | New Scientist - October 16th, 2022
- CRISPR-Cas9 Structures and Mechanisms - PubMed - October 16th, 2022
- A CRISPR cure for HIV? Gene-editing technology may be able stop viral replication in its tracks and wipe out infections - Genetic Literacy Project - October 16th, 2022
- Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene... - October 16th, 2022
- More Foods Will Be Gene-Edited Than You Think - The Epoch Times - October 16th, 2022
- What is CRISPR? - MD Anderson Cancer Center - September 21st, 2022
- CRISPR infusion eliminates swelling in those with rare genetic disease - Science - September 21st, 2022
- Crispr Therapeutics becomes the latest biotech to open in the Seaport - The Boston Globe - September 21st, 2022